| Symbol | ANVS |
|---|---|
| Name | ANNOVIS BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1055 WESTLAKES DRIVE,SUITE 300, BERWYN, Pennsylvania, 19312, United States |
| Telephone | +1 610 727-3913 |
| Fax | — |
| — | |
| Website | https://www.annovisbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinsons and Alzheimers diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301. Additional info from NASDAQ: |
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimers Disease 6-Month NDA Submission
Read moreNew Form 424B5 - Annovis Bio, Inc. <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001104659-26-041561 <b>Size:</b> 575 KB
Read moreAnnovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Read moreDirector Hoffman Michael B 🟢 acquired 713.8K shares of Annovis Bio, Inc. (ANVS) at $2.10 ($1.5M) Transaction Date: Apr 02, 2026 | Filing ID: 039675
Read more📋 White Mark K. (Director) plans to sell 7K shares of Annovis Bio, Inc. (at $2.08 each, total $15K) Filed: Apr 02, 2026 | ID: 000128
Read moreAnnovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Read moreAnnovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinsons Disease Study
Read moreAnnovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Read moreNew Form 10-K - Annovis Bio, Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001104659-26-027751 <b>Size:</b> 9 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07284784 | A Study of Buntanetap in Participants With PD | Phase2 | Parkinson's Disease (PD) | Recruiting | 2026-01-09 | 2029-11-01 | ClinicalTrials.gov |
| NCT06709014 | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Partic… | Phase3 | Early Alzheimers Disease | Recruiting | 2025-02-04 | 2028-06-01 | ClinicalTrials.gov |
| NCT04524351 | Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Pa… | Phase1 | Alzheimer Disease | Completed | 2020-08-14 | 2022-01-31 | ClinicalTrials.gov |
| NCT02925650 | Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's… | Phase1 | Alzheimer's Disease | Completed | 2017-03-02 | 2021-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| buntanetap/posiphen | Other | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Buntanetap/Posiphen | DRUG | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT05686044 |
| buntanetap/posiphen | DRUG | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Placebo | DRUG | Phase PHASE3 | Early Alzheimers Disease | RECRUITING | NCT06709014 |
| Posiphen | DRUG | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT04524351 |
| Posiphen® tartrate capsules | DRUG | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01072812 |